• <tbody id="eng4t"></tbody>

  • <dd id="eng4t"></dd>
  • <button id="eng4t"><acronym id="eng4t"></acronym></button> <button id="eng4t"></button>

    <span id="eng4t"></span>

    <rp id="eng4t"><object id="eng4t"></object></rp>
    1. <s id="eng4t"></s><samp id="eng4t"><tt id="eng4t"></tt></samp>
    2. <em id="eng4t"></em>
      <li id="eng4t"><acronym id="eng4t"></acronym></li>
    3. <em id="eng4t"><acronym id="eng4t"><u id="eng4t"></u></acronym></em>

      <em id="eng4t"><acronym id="eng4t"><u id="eng4t"></u></acronym></em>

      1. Artificial heart valves and transcather implantation systems
        The product which is interventive, minimally invasive, without surgical sutures and cardiopulmonary bypass is used to replace the diseased mitral valve. This new designed product can simplify the replacement surgery, significantly reducing the risks of treatment and increasing success rate. Moreover, this can shorten patients’ postoperative recovery time and cut down costs. Furthermore, reduced price of similar products enables more patients to have opportunities to endure risk and expense of surgery and treatment. As a revolutionary treatment, transcatheter artificial heart valve prosthesis is being well recognized by experts. In the future, clinical demands will grow explosively.
        人工心脏瓣膜及导管植入系统具有介入、无手术缝线、无需体外循环和无须开胸手术等特点,用于置换心脏内病变的二尖瓣瓣膜。 这种新型产品将使心脏瓣膜置换手术过程简化、治疗风险大幅降低、成功率将显著提高,同时也将缩短病人术后恢复时间及大大降低费用,拉低进口同类产品价格,使更多的病人能够承受手术的风险和费用而得到治疗。 介入人工心脏瓣膜作为一种革命性的治疗手段,正日益被专家所认同,在可预见的未来几年内,临床需求将会呈现爆发性的增长。
        韩国免费a级作爱片免费观看中国 亚洲中文av一区二区三区| h纯肉无修动漫无删减| 午夜性刺激免费看视频| 虏囚女教师~肉欲の放课后| 亚洲中文字幕日产乱码小说| 青青热久免费精品视频在| 在线观看国产成人av天堂| 免费永久观看美女裸体网站| 大地影院日本韩国免费播放| 色噜噜狠狼综合在线| 伦埋琪琪深夜福利|